RE:EPIX from US$1.6 to US$32 on P1 cancer data,18 months Great example, and nice pick for ya! Hearing Levesque yesterday it appears that he is using the share price as at least one indicator of corporate success (as it shoudl be) and he's not too pleased that it's lower than when he joined. It sure seemed to me they would update the market on any interesting findings as they go through the Phase 1 and like I mentioned before, quite often the percentage gains in the pre-clinical to Phase 1 data are the largest gains, as your example is showing.
Spartrap wrote: Here we go,that small canadian company ESSA Pharma I was talking about the other day just published first human data today. Briefly touched US$32 on the news (US$1B MC).
"One out of three patients who completed 12 weeks of therapy experienced a prostate-specific antigen decline (PSA) of more than 50% after three cycles of EPI-7386 therapy (12 weeks) with ongoing continued PSA declines continuing through six cycles of therapy, despite previously having failed enzalutamide and abiraterone acetate"
One patient response. 20 bagger. In 18 months. After huge dilution.
I was buying it as low as US$1.6 in august 2019 after a reverse merger followed by a raise. The RM diluted by roughly 100% in May 2019 and was quickly followed in August by a raise that was again another massive 130% dilutive.
SP went up regularly during all that time, with IND in March 2020 followed by P1 dosing in July 2020.
Then went into the US$20's on news than Jenssen wanted to collaborate for a combination trial back in January 13th. There you see it : Jenssen *new* about the response months before the data came out. That's the beauty of early open label trials. Leaks to BP.